MLASDO: a software tool to detect and explain clinical and omics inconsistencies applied to the Parkinson's Progression Markers Initiative cohort
Jos\'e A. Pardo, Tom\'as Bernal, Jaime \~Niguez, Ana Luisa Gil-Mart\'inez, Laura Iba\~nez, Jos\'e T. Palma, Juan A. Bot\'ia, Alicia G\'omez-Pascual

TL;DR
MLASDO is a novel software tool that detects and explains inconsistencies between clinical and omics data in medical cohorts, aiding in early disease detection and cohort analysis.
Contribution
This paper introduces MLASDO, a new method and open-source R package for identifying and explaining anomalous samples using omics and clinical data.
Findings
Detected 15 HC with PD-like signatures and clinical features
Identified 22 PD cases with HC-like transcriptomic signatures
Demonstrated MLASDO's utility in clinical cohort analysis
Abstract
Inconsistencies between clinical and omics data may arise within medical cohorts. The identification, annotation and explanation of anomalous omics-based patients or individuals may become crucial to better reshape the disease, e.g., by detecting early onsets signaled by the omics and undetectable from observable symptoms. Here, we developed MLASDO (Machine Learning based Anomalous Sample Detection on Omics), a new method and software tool to identify, characterize and automatically describe anomalous samples based on omics data. Its workflow is based on three steps: (1) classification of healthy and cases individuals using a support vector machine algorithm; (2) detection of anomalous samples within groups; (3) explanation of anomalous individuals based on clinical data and expert knowledge. We showcase MLASDO using transcriptomics data of 317 healthy controls (HC) and 465 Parkinson's…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
